Literature DB >> 28450944

Evaluation of optimized magnetic resonance perfusion imaging scanning time window after contrast agent injection for differentiating benign and malignant breast lesions.

Jie Dong1, Dawei Wang1, Zhenshen Ma1, Guodong Deng2, Lanhua Wang3, Jiandong Zhang2.   

Abstract

The aim of the study was evaluate the 3.0 T magnetic resonance (MR) perfusion imaging scanning time window following contrast injection for differentiating benign and malignant breast lesions and to determine the optimum scanning time window for increased scanner usage efficiency and reduced diagnostic adverse risk factors. A total of 52 women with breast abnormalities were selected for conventional MR imaging and T1 dynamic-enhanced imaging. Quantitative parameters [volume transfer constant (Ktrans), rate constant (Kep) and extravascular extracellular volume fraction (Ve)] were calculated at phases 10, 20, 30, 40 and 50, which represented time windows at 5, 10, 15, 20 and 25 min, respectively, following injection of contrast agent. The association of the parameters at different phases with benign and malignant tumor diagnosis was analyzed. MR perfusion imaging was verified as an effective modality in the diagnosis of breast malignancies and the best scanning time window was identified: i) Values of Ktrans and Kep at all phases were statistically significant in differentiating benign and malignant tumors (P<0.05), while the value of Ve had statistical significance only at stage 10, but not at any other stages (P>0.05); ii) values of Ve in benign tumors increased with phase number, but achieved no obvious changes at different phases in malignant tumors; iii) the optimum scanning time window of breast perfusion imaging with 3.0 T MR was between phases 10 and 30 (i.e., between 5 and 15 min after contrast agent injection). The variation trend of Ve values at different phases may serve as a diagnostic reference for differentiating benign and malignant breast abnormalities. The most efficient scanning time window was indicated to be 5 min after contrast injection, based on the observation that the Ve value only had statistical significance in diagnosis at stage 10. However, the optimal scanning time window is from 5 to 15 min following the injection of contrast agent, since that the variation trend of Ve is able to serve as a diagnostic reference.

Entities:  

Keywords:  breast lesions; magnetic resonance imaging; malignant and benign; perfusion imaging; scanning time window

Year:  2017        PMID: 28450944      PMCID: PMC5403584          DOI: 10.3892/etm.2017.4060

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  17 in total

1.  Meta-analysis of MR imaging in the diagnosis of breast lesions.

Authors:  Nicky H G M Peters; Inne H M Borel Rinkes; Nicolaas P A Zuithoff; Willem P T M Mali; Karel G M Moons; Petra H M Peeters
Journal:  Radiology       Date:  2007-11-16       Impact factor: 11.105

2.  3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.

Authors:  Riham H El Khouli; Katarzyna J Macura; Ihab R Kamel; Michael A Jacobs; David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2011-12       Impact factor: 3.959

Review 3.  Molecular imaging for the characterization of breast tumors.

Authors:  Heinrich Florian Magometschnigg; Thomas Helbich; Peter Brader; Oshaani Abeyakoon; Pascal Baltzer; Barbara Füger; Georg Wengert; Stephan Polanec; Hubert Bickel; Katja Pinker
Journal:  Expert Rev Anticancer Ther       Date:  2014-02-19       Impact factor: 4.512

Review 4.  Multiparametric MR Imaging of Breast Cancer.

Authors:  Habib Rahbar; Savannah C Partridge
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

5.  Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.

Authors:  Hyeon-Man Baek; Jeon-Hor Chen; Ke Nie; Hon J Yu; Shadfar Bahri; Rita S Mehta; Orhan Nalcioglu; Min-Ying Su
Journal:  Radiology       Date:  2009-03-10       Impact factor: 11.105

6.  Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.

Authors:  Iclal Ocak; Marcelino Bernardo; Greg Metzger; Tristan Barrett; Peter Pinto; Paul S Albert; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2007-10       Impact factor: 3.959

7.  DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings.

Authors:  Xia Li; Lori R Arlinghaus; Gregory D Ayers; A Bapsi Chakravarthy; Richard G Abramson; Vandana G Abramson; Nkiruka Atuegwu; Jaime Farley; Ingrid A Mayer; Mark C Kelley; Ingrid M Meszoely; Julie Means-Powell; Ana M Grau; Melinda Sanders; Sandeep R Bhave; Thomas E Yankeelov
Journal:  Magn Reson Med       Date:  2013-05-09       Impact factor: 4.668

8.  Quantitative analysis of 3-Tesla magnetic resonance imaging in the differential diagnosis of breast lesions.

Authors:  Zhen-Shen Ma; DA-Wei Wang; Xiu-Bin Sun; Hao Shi; Tao Pang; Gui-Qing Dong; Cheng-Qi Zhang
Journal:  Exp Ther Med       Date:  2014-12-22       Impact factor: 2.447

9.  MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy.

Authors:  Ella F Jones; Sumedha P Sinha; David C Newitt; Catherine Klifa; John Kornak; Catherine C Park; Nola M Hylton
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  Role of quantitative pharmacokinetic parameter (transfer constant: K(trans)) in the characterization of breast lesions on MRI.

Authors:  Jena Amarnath; Taneja Sangeeta; Shashi Bhushan Mehta
Journal:  Indian J Radiol Imaging       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.